Pages that link to "Q80358653"
Jump to navigation
Jump to search
The following pages link to Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system (Q80358653):
Displaying 50 items.
- MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU (Q21136391) (← links)
- Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction (Q24197765) (← links)
- Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction (Q24202513) (← links)
- Challenges in translating endpoints from trials to observational cohort studies in oncology (Q26746190) (← links)
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology (Q26797522) (← links)
- Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research (Q26995439) (← links)
- MicroRNA-10b and breast cancer metastasis (Q28298453) (← links)
- Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel (Q28728830) (← links)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer (Q29011698) (← links)
- Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma (Q30432609) (← links)
- Reporting methods in studies developing prognostic models in cancer: a review (Q30494142) (← links)
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration (Q30514241) (← links)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial (Q30758991) (← links)
- Incorporating clinical trial data into daily cancer care (Q30836868) (← links)
- Response assessment criteria for brain metastases: proposal from the RANO group. (Q30969912) (← links)
- Improving cancer outcomes through international collaboration in academic cancer treatment trials (Q33561197) (← links)
- Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study (Q33564813) (← links)
- Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer (Q33591401) (← links)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer (Q33631047) (← links)
- Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms (Q33651520) (← links)
- The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Onco (Q33739381) (← links)
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study (Q33824842) (← links)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). (Q33883406) (← links)
- Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). (Q33913615) (← links)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (Q33927979) (← links)
- Circulating tumor cells predict survival in early average-to-high risk breast cancer patients (Q33958981) (← links)
- Overexpression of POLQ confers a poor prognosis in early breast cancer patients (Q34051213) (← links)
- Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study (Q34109691) (← links)
- Long-term prognostic role of functional limitations among women with breast cancer (Q34176406) (← links)
- Genomic index of sensitivity to endocrine therapy for breast cancer. (Q34193932) (← links)
- Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer (Q34252411) (← links)
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study (Q34325583) (← links)
- ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer (Q34334333) (← links)
- Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. (Q34334964) (← links)
- The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. (Q34478536) (← links)
- Metabolic syndrome and outcomes following early-stage breast cancer (Q34539016) (← links)
- Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co (Q34640536) (← links)
- Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer (Q34682560) (← links)
- What can be learnt about disease progression in breast cancer dormancy from relapse data? (Q34720547) (← links)
- The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis (Q34745747) (← links)
- Adjuvant chemotherapy in older women with early-stage breast cancer (Q34858284) (← links)
- Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG) (Q34907190) (← links)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (Q35038093) (← links)
- High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. (Q35065084) (← links)
- The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer (Q35202833) (← links)
- Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization (Q35204515) (← links)
- Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. (Q35230269) (← links)
- Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. (Q35450768) (← links)
- Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. (Q35558084) (← links)
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up (Q35607675) (← links)